Literature DB >> 3190187

Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects.

R Farinotti1, J H Trouvin, V Bocquet, N Vermerie, C Carbon.   

Abstract

The pharmacokinetics of ofloxacin were investigated in eight healthy male volunteers. A single infusion (200 mg over 0.5 h) was performed on day 1, followed by a washout period of 2 weeks. Repeated administrations were performed for 4 days (200 mg every 12 h). Pharmacokinetic parameters were determined from the plasma decay curves of the single and the last of the multiple administrations. Ofloxacin kinetics after the single dose were best described by a two-phase curve with a total body clearance of 241.6 +/- 43.3 ml min-1, a volume of distribution of 112 +/- 23.1 liters, and an elimination half-life of 5.4 +/- 0.8 h. The extrapolated area under the curve (AUC0-infinity) was 14 +/- 2.3 mg.h liter-1. The pharmacokinetics were not significantly modified by repeated administration, demonstrated mainly by the AUC0-12 value of the last infusion (13.4 +/- 2.2 mg.h liter-1). We conclude that, with intravenous multiple doses every 12 h, the steady state is reached within 24 to 36 h and no abnormal accumulation or changes in pharmacokinetic parameters occur.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190187      PMCID: PMC175926          DOI: 10.1128/AAC.32.10.1590

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Pharmacokinetics of ofloxacin after parenteral and oral administration.

Authors:  H Lode; G Höffken; P Olschewski; B Sievers; A Kirch; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

2.  Ofloxacin pharmacokinetics in renal failure.

Authors:  J P Fillastre; A Leroy; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

3.  Ofloxacin: serum and skin blister fluid pharmacokinetics in the fasting and non-fasting state.

Authors:  T Kalager; A Digranes; T Bergan; T Rolstad
Journal:  J Antimicrob Chemother       Date:  1986-06       Impact factor: 5.790

4.  Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent.

Authors:  E E Dagrosa; M Verho; V Malerczyk; S de Looze; P Hajdú; K Toyodera
Journal:  Clin Ther       Date:  1986       Impact factor: 3.393

5.  The effect of food on the pharmacokinetics of ofloxacin.

Authors:  M Verho; V Malerczyk; E Dagrosa; A Korn
Journal:  Curr Med Res Opin       Date:  1986       Impact factor: 2.580

Review 6.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

  6 in total
  9 in total

1.  Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.

Authors:  M Boeckh; H Lode; K M Deppermann; S Grineisen; F Shokry; R Held; K Wernicke; P Koeppe; J Wagner; C Krasemann
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 2.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever.

Authors:  D B Bethell; N P Day; N M Dung; C McMullin; H T Loan; D T Tam; L T Minh; N T Linh; N Q Dung; H Vinh; A P MacGowan; L O White; N J White
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers.

Authors:  Max Taubert; Joseph Chiesa; Mark Lückermann; Carsten Fischer; Axel Dalhoff; Uwe Fuhr
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 5.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

6.  Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers.

Authors:  J H Yuk; C H Nightingale; R Quintiliani; K R Sweeney
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

7.  Treatment of experimental endocarditis due to ampicillin-susceptible or ampicillin-resistant Salmonella enteritidis.

Authors:  M L Fernández Guerrero; R Torres Perea; C Verdejo Morcillo; R Fernández Roblas; M de Górgolas
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

8.  Ofloxacin pharmacokinetics in mechanically ventilated patients.

Authors:  C Martin; D Lambert; B Bruguerolle; P Saux; J Freney; J Fleurette; H Meugnier; F Gouin
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

9.  High-pressure liquid chromatography and microbiological assay of serum ofloxacin levels in adults receiving intravenous and oral therapy for skin infections.

Authors:  G M Auten; L C Preheim; M Sookpranee; M J Bittner; T Sookpranee; A Vibhagool
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.